ZNF564

Across TCGA pan-cancer cohorts, ZNF564 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of ZNF564’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ZNF564 RNA is repressed in tumor relative to normal tissue. In most cancer types ZNF564 is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, LIHC, and BLCA are the cancer types where ZNF564 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF564 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.600	<.001	10	view →
LIHC	All	All	+0.152	<.001	6	view →
BLCA	Female	III,IV	+0.332	.008	5	view →
COAD	Female	All	−0.397	<.001	4	view →
BRCA	All	All	+0.148	.008	4	view →
KIRC	All	All	−0.125	.003	4	view →
CHOL	All	All	+0.441	<.001	3	view →
LUAD	Female	II,III,IV	−0.210	.023	3	view →
STAD	All	II,III,IV	+0.186	.010	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

ZNF564–THCA

Open the THCA breakdown →